Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone, Rossella Galati

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.

Original languageEnglish
Article number69
JournalMolecular Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - Mar 21 2014

Fingerprint

exemestane
Mesothelioma
Down-Regulation
Pemetrexed
Growth
Cell Movement
Therapeutics
Aromatase Inhibitors
Aromatase
S Phase
Heterografts
Cisplatin
Cell Survival
Cell Cycle
Cell Proliferation

Keywords

  • Aromatase
  • Exemestane
  • Mesothelioma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Medicine(all)

Cite this

Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. / Nuvoli, Barbara; Germoni, Sabrina; Morosetti, Carlotta; Santoro, Raffaela; Cortese, Giancarlo; Masi, Serena; Cordone, Iole; Galati, Rossella.

In: Molecular Cancer, Vol. 13, No. 1, 69, 21.03.2014.

Research output: Contribution to journalArticle

Nuvoli, Barbara ; Germoni, Sabrina ; Morosetti, Carlotta ; Santoro, Raffaela ; Cortese, Giancarlo ; Masi, Serena ; Cordone, Iole ; Galati, Rossella. / Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. In: Molecular Cancer. 2014 ; Vol. 13, No. 1.
@article{3d1858e83b8244009ff635a6f356ff1a,
title = "Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease",
abstract = "Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.",
keywords = "Aromatase, Exemestane, Mesothelioma",
author = "Barbara Nuvoli and Sabrina Germoni and Carlotta Morosetti and Raffaela Santoro and Giancarlo Cortese and Serena Masi and Iole Cordone and Rossella Galati",
year = "2014",
month = "3",
day = "21",
doi = "10.1186/1476-4598-13-69",
language = "English",
volume = "13",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

AU - Nuvoli, Barbara

AU - Germoni, Sabrina

AU - Morosetti, Carlotta

AU - Santoro, Raffaela

AU - Cortese, Giancarlo

AU - Masi, Serena

AU - Cordone, Iole

AU - Galati, Rossella

PY - 2014/3/21

Y1 - 2014/3/21

N2 - Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.

AB - Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.

KW - Aromatase

KW - Exemestane

KW - Mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=84897520713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897520713&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-13-69

DO - 10.1186/1476-4598-13-69

M3 - Article

C2 - 24655565

AN - SCOPUS:84897520713

VL - 13

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 69

ER -